PaNcryos Offering  

Private Placement



Use of funds

Shares (with buy back option)




Sector Biotech – stem cell
Key Market Data  
Market Private Offering
Price per Share €1,500
Number of shares for sale 3,334
Total €5,000,000.00
Company Valuation €60,000,000
Share buy back option 3-5 years
Fiscal Year end 31st December
Company Objective Growth

Main Shareholders


Management Team 100%

PaNcryos – €5m share offering.

PaNcryos is a pre-clinical stage biotech company, dedicated to improving life quality for millions of people suffering from Type 1 diabetes (T1D), by developing a best-in-class stem cell derived beta cell therapy, called PanInsula(TM).

T1D is a chronic autoimmune disease that affects millions of people worldwide and requires lifelong insulin injections to manage blood glucose levels. Despite advances in insulin delivery and monitoring devices, many patients still face serious complications such as kidney failure, blindness, nerve damage and cardiovascular disease.

There is an urgent need for a safe, effective, and scalable cell replacement therapy that can restore natural insulin production and improve quality of life for people with T1D. The global prevalence and incidence of T1D is set to increase due to changes in lifestyle and environmental factors. The overall level of unmet need in the T1D treatment space, coupled with the rising prevalence of T1D, present a big opportunity for drug developers to fulfill the remaining gaps in treatment.